Key Approvals Secured
Cronos Group Shareholders Approve Directors, Executive Pay, and Auditor for 2026
Cronos Group Inc. held its 2026 Annual Meeting of Shareholders on June 18, with 72.24% of outstanding common shares — about 271.8 million shares — cast in person or by proxy, according to Financial Post. Shareholders elected all seven director nominees, overwhelmingly backed executive pay, and approved the company's auditor for the year ahead.
The results signal strong investor confidence in management. The "say-on-pay" advisory vote — where shareholders weigh in on executive compensation — passed with 99.09% support, or roughly 219.8 million votes in favor, Financial Post reported.
All Seven Directors Elected with Strong Shareholder Backing
Every director nominated in Cronos's proxy statement won a seat on the board. Jason Adler and Darren Broughton led the pack, each pulling 99.42% support. CEO and Chairman Michael Gorenstein earned the least support among nominees but still cleared 93.67% — a comfortable margin by any measure, according to Financial Post.
Other elected directors include Murray Garnick, Dominik Meier, Elizabeth Seegar, and James Rudyk, who serves as Lead Director and Audit Chair. Rudyk previously held senior roles at Roots and Shred-It, and oversees the company's financial integrity.
Davidson & Company Rehired as Auditor Despite Past SEC Charges
Shareholders voted to keep Davidson & Company LLP as Cronos's independent auditor for fiscal year 2026. The Vancouver-based firm received roughly 268.5 million votes in favor — about 98.7% support. The appointment was routine in practice, though not without controversy.
In December 2024, the U.S. Securities and Exchange Commission charged Davidson & Company with auditor independence violations, according to Montreal Gazette. Shareholders appear to be betting on continuity over a fresh audit relationship, especially as Cronos pursues expansion into Europe.
40% Revenue Jump and $822 Million Cash Pile Fuel Investor Optimism
The meeting came on the heels of a strong first quarter. Cronos posted $45.2 million in Q1 2026 revenue — a 40% jump year over year. The company also holds roughly $822 million in cash, giving it an Altman Z-score of 12.91, a number that signals very low bankruptcy risk, according to Edmonton Examiner.
In May 2026, Cronos launched a $50 million share repurchase program, later extending it to the Toronto Stock Exchange. Analysts at TD Securities lifted their price targets for the stock, pointing to the company's 10.4% Canadian vape market share and what they called "rescheduling tailwinds" from U.S. federal cannabis policy changes, The Sudbury Star noted.
U.S. Cannabis Rescheduling Adds Opportunity — and New Compliance Costs
The annual meeting also unfolded against a major policy shift. A federal executive order in late 2025 directed the DEA to move marijuana from Schedule I to Schedule III. That change removes the punishing Section 280E tax burden on cannabis companies — a rule that had blocked businesses from deducting normal operating expenses, Daily Herald Tribune reported.
But the shift is not a free pass. Cronos and its peers must register with the DEA by late June 2026, adding a "new layer of federal compliance" that could raise administrative costs even as taxes ease. Legal experts caution that rescheduling is "not a solution" for the lack of banking reform or interstate commerce rules, leaving key structural barriers in place.
Sentiment
NeutralPublishers
10
Articles
9
Reach
10
